Trial Profile
Five year observational follow-up of the IVAN trial cohort: a study of function and morphology
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Feb 2019
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Ranibizumab
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- Acronyms IVAN Follow Up
- 07 Feb 2019 Status changed from recruiting to completed.
- 18 Apr 2016 New trial record